Abstract:Background:B lymphocytes (B cells) are essential in humoral response, and their activation is an important first step for the production of antibodies. However, aberrant B-cell activation is common in the development and progression of autoimmune diseases including systemic lupus erythematosus (SLE), which is characterized by the generation of superfluous autoantibodies. SLE exhibits clinical manifestation such as excessive inflammation and tissue damage. This review aims to summarize the recent emerging studies on aberrant B-cell activation and the associated concurrent therapeutic targets in SLE. Summary:Aberrant B-cell activation is closely associated with the pathogenesis of SLE. Among a variety of mechanisms, dysregulations of B-cell receptor (BCR), toll-like receptor (TLR), and B-cell activating factor receptor (BAFF-R) pathways are the common and dominating factors involved in aberrant B-cell activation. These aberrant signaling transductions play diverse and integrated roles in the development and the pathogenesis of SLE. Therapies targeting aberrant B-cell activation have shown promising efficacy in achieving the clinical alleviation of SLE, suggesting the discovery of new drug targets from these aberrant signaling pathways is imminent. Here, an integrated survey or review of published high-throughput sequencing database covering RNAs of B cells from SLE versus criteria-matched healthy controls highlights that reported signaling molecules in BCR pathway (VAV2, PLC-γ2), TLR pathway (TLR9, P105, IRF7, TAB1), and BAFF-R pathway (SDF-1α) are attitudinally upregulated in SLE patients. This review thus suggests the concurrent and future therapeutic targets and potential biomarkers in both basic and clinical studies of SLE. Key Messages:This review focuses on core B-cell signaling pathways, discussing the progress in the role of aberrant B-cell activation during the pathogenesis of SLE. This review also highlights the signaling molecules from published studies and database for the possible prevention and treatment targets serving the future clinical treatments of SLE.

Toll-like receptor signalling in B cells during systemic lupus erythematosus

Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus

Post-translational Modifications in T Cells in Systemic Erythematosus Lupus

Human and Murine Toll-like Receptor-Driven Disease in Systemic Lupus Erythematosus

The Largely Normal Response to Toll-Like Receptor 7 and 9 Stimulation and the Enhanced Expression of SIGIRR by B Cells in Systemic Lupus Erythematosus

B cell autophagy mediates TLR7-dependent autoimmunity and inflammation

The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus

Aberrant B-Cell Activation in Systemic Lupus Erythematosus.

Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus

TLR4+CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus

B cells expressing the transcription factor T-bet drive lupus-like autoimmunity

The B cell response to both protein and nucleic acid antigens displayed on apoptotic cells are dependent on endosomal pattern recognition receptors

T Follicular Helper Cells and Regulatory B Cells Dynamics in Systemic Lupus Erythematosus.

Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis

The abnormal signaling of the B cell receptor and co-receptors of lupus B cells

Regulatory B cell and Systemic Lupus Erythematosus

Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients

B cell biology and dysfunction in SLE

TLR10 expression in unswitched memory B associates with the disease activity of patients with systemic lupus erythematosus

Follicular Helper T Cells in Systemic Lupus Erythematosus: a Potential Therapeutic Target.

T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis